Background The long-term success of coronary bypass surgery is dependent on graft patency after surgery. This trial was designed to determine if aspirin improved saphenous vein graft or internal mammary artery (IMA) graft patency between 1 and 3 years after coronary artery bypass grafting (CABG).
Methods and Results After receiving aspirin 325 mg/d for 1 year after CABG and undergoing a 1-year postoperative cardiac catheterization, patients were randomized to receive either aspirin (325 mg) or placebo for 2 additional years. Angiography was performed 3 years after surgery to determine the primary end point-saphenous vein graft patency in 288 patients and IMA graft patency in 167 patients. At 3 years after CABG, the saphenous vein graft occlusion rate was 17.0% (62 of 365) for patients treated with aspirin compared T he long-term success of coronary artery bypass surgery is dependent on graft patency after surgery. It is well established that aspirin (325 mg/d) improves saphenous vein graft patency early (7 to 10 days) and later (1 year) after coronary artery surgery.1-3 Based on this information, this Department of Veterans Affairs Cooperative Trial was designed to determine if aspirin improved saphenous vein graft or internal mammary artery (IMA) graft patency between 1 and 3 years after coronary artery surgery. The results presented are a continuation of our ongoing study of the effects of antiplatelet agents on graft patency after coronary artery bypass grafting (CABG).
The purpose of this prospective, centrally directed, randomized, double-blind, placebo-controlled trial was twofold. The first objective was to compare the effects on early (7-to 10-day) graft patency of aspirin therapy initiated before surgery with those of aspirin initiated 6 hours after surgery. The results of this phase of the study have been published.4 The second objective, which is the topic of the present report, was to examine the effects of aspirin on graft patency 3 years after surgery.
Because aspirin was found to be effective in reducing graft occlusions 1 year after surgery in our previous study, all patients in this trial received aspirin (325 mg once daily) for 1 year after CABG. A cardiac catheterization was obtained at 1 year after surgery, and at this point patients were randomized to either aspirin (325 mg/d) or placebo for 2 additional years. The hypothesis was that aspirin would improve graft patency through 3 years after surgery.
1991. The exclusion criteria, definition of the study population, and stratification techniques have been previously described. [1] [2] [3] [4] Of the 374 patients who underwent the 1-year postoperative catheterization, 334 of these 374 patients (89%) agreed to participate in the long-term phase of the study and were randomized and prospectively followed for an additional 2 years. Two hundred eighty-eight (86%) of these 334 patients underwent the 3-year postoperative catheterization.
Treatment Regimens
After receiving aspirin (325 mg) daily for 1 year after surgery and undergoing a 1-year postoperative catheterization, patients were randomized to receive either aspirin (325 mg) into an integrated image processor-computer system. Images were then redisplayed on the integrated memory plane, absolute measurements were made, and stenoses were calculated for all vessels .1 mm in diameter. The number, type, and size of all grafts were recorded using an interactive computer program. Images of the cineframes, with the measurements superimposed, were filmed for storage in hard copy format. The angiographic analysis used in this study was prospective. The size of the distal vessel was analyzed by measuring the lumen of the vessel from the cinefilm. To determine the absolute lumen diameter of the distal vessel, the diameter of the catheter was measured. The appropriate magnification factor was calculated by knowing the actual diameter of the catheter. Actual vessel size was reported using this correction factor.
A single-vein or IMA graft was defined as patent when the origin was visualized and contrast material opacified the graft and the distal vessel, either by selective injection or by aortic root angiography. When analyzing sequential-or Y-vein grafts, a distal anastomosis (either side-to-side or end-to-side) was defined as patent if the contrast material was seen to flow from the vein graft into the grafted artery. If the graft was occluded at its origin, all associated distal anastomoses were considered occluded. If one distal anastomosis of a Y-or sequential-vein graft was occluded, that site was defined as an occluded graft. When there was a difference of opinion regarding patency, the films were reviewed, and a consensus opinion was reported.
Statistical Analysis
Data are given as mean±SD unless otherwise specified.
Comparability of treatment groups was tested using the x2 statistic on qualitative variables. Quantitative variables were evaluated using the Student's t test for normally distributed data and the Wilcoxon rank-sum test for non-normally distributed data. The patency data were analyzed in two ways: (1) by comparison of grafts that were occluded, assuming the grafts to be dependent, and (2) by comparison of the proportion of patients with one or more occluded grafts. Because our previous data showed that there was a dependency of graft patency among individual patients, a cluster sampling approach was used to define the variance for the first type of analysis.5 In the second type of analysis, the unit of measure (patient) is independent, as is the case with IMA grafts, because there is only one graft per patient. In these analyses, the Z statistic is used to compare differences between two proportions.
Results

Patient Data
Of the 334 patients entered into the study, catheterization was not performed in 46 patients because of patient refusal in 9, withdrawal from study in 22, death in 7, and other medical problems in 5 patients. Catheterization was deferred in 3 patients secondary to technical difficulties. The remaining 288 patients (86%) underwent the postoperative catheterization. This report contains the data on 288 of 334 patients (86%) with vein grafts who underwent catheterization within 3 years of surgery and whose data were available in the central angiographic laboratory. Films were destroyed on 5 patients, so only local data were available for these patients. Five patients ultimately received only an IMA graft at surgery even though the decision was originally made before randomization to use at least one saphenous vein graft. The angiographic data on these 5 individuals are included in only the IMA analyses. The median time from surgery to catheterization was 3.0 years (range, 2.2 to 4.1 years) for the 288 patients in this report. Ninety-five percent of the catheterizations were done between 2.8 years and 3.3 years after surgery. Figure. IMA Graft Occlusion Data At 3 years, the IMA graft occlusion rate was 10.3% (8 of 78) for patients treated with aspirin compared with 7.9% (7 of 89) for patients treated with placebo (P=.594). If an IMA graft was patent at 1 year, the occlusion rate was 4.3% (3 of 70) for patients treated with aspirin compared with 2.5% (2 of 81) for patients treated with placebo (P=.541).
The 3-year IMA patency data based on size of the distal vessel are also shown in Table 4 
Complications of Angiography
There were no incidences of myocardial infarction, cerebrovascular accident, or death during the 1-year and 3-year postoperative catheterizations. The only significant complications were ventricular fibrillation requiring direct-current countershock in one Months Post-op
Plot of serial occlusion rates for the early, 1-year, and 3-year catheterizations after coronary artery bypass grafting. Occlusion rate data are presented as mean+SD. All patients received aspirin for 1 year, with the first dose starting 6 hours after surgery (post-op) and continuing to the 1-year catheterization. The randomization between aspirin (E) and placebo (V) occurred after the 1-year catheterization. Patients were followed for 2 additional years and then underwent the 3-year catheterization. The two lines show the serial occlusion rates for the two patient groups as they were randomized after the 1-year catheterization. No difference in occlusion rates at 9 days and 1 year indicates that the two groups were comparable at randomization. No difference in occlusion rates at 3 years indicates that aspirin had no effect between 1 and 3 years after surgery. The present study provides the first prospective examination of the long-term patency of saphenous vein and IMA grafts in middle-aged men (average age, 59 years). Based on data from our previous study,1"2 most of the benefit from aspirin appears to occur in the immediate perioperative period. By 7 to 10 days after surgery, 6% to 8% of vein grafts occlude when patients are treated with aspirin (325 mg) daily compared with 15% of vein grafts when patients are given placebo. The previous study4 showed that aspirin (325 mg) could be started 6 hours after surgery rather than 12 hours before surgery without resulting in a significant increase in 7-to 10-day vein graft occlusion rate and with the benefit of reducing bleeding complications. A previous study2 also showed that in vein grafts patent at 7 to 10 days, aspirin given for 1 year did not significantly reduce the 1-year occlusion rate compared with placebo (8.7% versus 9.4%, respectively; P=.763). Likewise, the present study shows that for vein grafts patent at 1 year, aspirin given for 3 years did not significantly reduce the 3-year occlusion rate compared with placebo (4.8% versus 4.2%, respectively; P=.757). These data suggest that to reduce vein graft occlusion, aspirin must be given only during the perioperative period. However, it is important to note that if aspirin had been discontinued at any time between the early postoperative period and 1 year, the occlusion rate could have been higher at 1 year, and that patients with native coronary artery disease benefit from chronic aspirin administration. Although it is generally believed that vein grafts to the left anterior descending coronary artery have an improved patency rate compared with grafts to other vessels, we found no differences in patency rates to the different branches of the coronary arteries (Table 3) .
Although the results of this trial showed that aspirin treatment did not improve the 3-year patency rates of vein or IMA grafts, this conclusion assumes that patients in the placebo group did not inadvertently take aspirin. To minimize this possibility, all medication was provided in individualized patient kits, each containing a 12-month supply of medication bottles. All patients were instructed not to take aspirin or any aspirincontaining medicines for the duration of the study. For pain, patients were instructed to take acetaminophen or salsalate, and to help patients avoid taking aspirincontaining compounds, they were provided with a list of over-the-counter medicines that contain aspirin.
Compliance, as measured by pill counts, was excellent. Although we did not use a biochemical measure of compliance, ie, measurements of urinary salicylates, previous work from our study group has found that the correlation between pill counts and urine salicylates is excellent. 2 To our knowledge, these data are the first long-term graft patency data obtained from a prospectively designed study. It is not clear what the longer-term fate of these grafts will be. Previous angiographic studies have reported 10-year patency rates of 90% to 95% for IMA grafts and about 50% for saphenous vein grafts.6-8 However, this information was not obtained from prospectively designed trials. The patients were operated on in the early 1970s, when antiplatelet therapy and risk factor modification were not routinely used. Moreover, surgical techniques have been modified with regard to preparation of the vein graft before implantation. It is our intention to address the question of long-term patency in this prospective trial by obtaining catheterization data at 10 years. We hope to obtain more long-term patency data for both saphenous vein and IMA grafts.
